Kobayashi Pharmaceutical Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
735.8K | -0.18% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
462.6K | +0.13% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
330.6K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
160.8K | +4.28% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Equity ETF
|
116.7K | -0.17% | |
|
MFS Series Trust V-MFS International New Discovery Fund
|
114.0K | 0.00% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥104 | +2.0% |
| 2024 | ¥102 | +1.0% |
| 2023 | ¥101 | +12.2% |
| 2022 | ¥90 | +8.4% |
| 2021 | ¥83 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥155,252M | ¥166,258M | ¥173,455M | ¥165,600M |
| Gross Profit | ¥88,773M | ¥92,331M | ¥96,375M | ¥87,603M |
| Operating Income | ¥26,071M | ¥26,674M | ¥25,784M | ¥24,869M |
| Pretax Income | ¥27,654M | ¥27,968M | ¥27,588M | ¥13,942M |
| Net Income | ¥19,715M | ¥20,022M | ¥20,338M | ¥10,067M |
| EPS | ¥252.36 | ¥259.59 | ¥268.16 | ¥135.42 |
| Operating Margin | 16.79% | 16.04% | 14.86% | 15.02% |
| Balance Sheet | ||||
| Total Assets | ¥252,554M | ¥255,827M | ¥267,473M | ¥265,368M |
| Total Equity | ¥195,599M | ¥197,899M | ¥204,816M | ¥213,466M |
| Total Liabilities | ¥56,955M | ¥57,928M | ¥62,657M | ¥51,902M |
| Cash | ¥95,024M | ¥96,233M | ¥71,536M | ¥50,873M |
| Interest-bearing Debt | ¥630M | ¥792M | ¥987M | ¥846M |
| Equity Ratio | 77.45% | 77.36% | 76.57% | 80.44% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥22,419M | ¥31,914M | ¥18,360M | ¥11,246M |
| Investing CF | ¥7,991M | -¥14,312M | -¥19,576M | -¥18,415M |
| Financing CF | -¥10,377M | -¥20,759M | -¥19,463M | -¥7,768M |
| Free CF | ¥18,234M | ¥15,685M | ¥4,791M | -¥15,383M |
| Efficiency | ||||
| ROE | 10.08% | 10.12% | 9.93% | 4.72% |
| ROA | 7.81% | 7.83% | 7.60% | 3.79% |
Latest IR Information
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥5,514
Rating Score: 2.63 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
About Us - FinancialContent ↗
Despite leadership changes, Kobayashi Pharma still struggling with reform - The Japan Times ↗
About Us - FinancialContent ↗
Company Information
About
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, sanitary and paper products, hand warmers, aloe products, displays, models, mouthpieces, and kaiko; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, and asset management activities. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
